Tempus and Recursion Extend Data Partnership Through November 2029
Tempus AI, Inc. announced on September 21, 2026 that it has extended its data license agreement with Recursion Pharmaceuticals, Inc. through November 2029, and that the two companies have entered into a separate agreement under which Tempus will license Recursion’s…
Adaptive Highlights NCCN Myeloma Guideline Updates Naming clonoSEQ
Adaptive Biotechnologies Corporation announced on September 17, 2026, that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Multiple Myeloma, adding for the first time a dedicated page outlining principles of minimal residual disease…
EviCore to Cover Guardant Health Shield Colorectal Cancer Blood Test
In a September 14, 2026 announcement, Guardant Health said its Shield blood test for colorectal cancer screening will be covered in EviCore by Evernorth clinical guidelines effective January 1, 2027, per American Cancer Society guidelines. The Palo Alto, California-based precision…
Tempus Wins Up to $9.5 Million ARPA-H Award for Heart Failure AI Agent
Tempus AI, Inc. announced on September 9, 2026 that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to…
Guardant360 CDx Wins FDA Nod as Companion Diagnostic for Camizestrant
Guardant Health announced on September 4, 2026 that the U.S. Food and Drug Administration has approved its Guardant360 CDx blood test as a companion diagnostic for Etcamah (camizestrant), AstraZeneca’s oral selective estrogen receptor degrader, in advanced breast cancer. The FDA…
Tempus Clears Third FDA Cardiac Algorithm: Pulmonary Hypertension ECG Test
Tempus AI has received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH, an AI-enabled software device that reads standard 12-lead electrocardiograms for signs associated with pulmonary hypertension — the third FDA-cleared algorithm in the company’s cardiovascular…
